We serve Chemical Name:2-(3,4-dimethoxyphenyl)sulfonylethanol CAS:688763-13-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(3,4-dimethoxyphenyl)sulfonylethanol
CAS.NO:688763-13-5
Synonyms:2-(3,4-dimethoxyphenyl)sulfonylethanol
Molecular Formula:C10H14O5S
Molecular Weight:246.28000
HS Code:2909499000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:81.21000
Exact Mass:246.05600
LogP:1.55060
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(3,4-dimethoxyphenyl)sulfonylethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(3,4-dimethoxyphenyl)sulfonylethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3,4-dimethoxyphenyl)sulfonylethanol Use and application,2-(3,4-dimethoxyphenyl)sulfonylethanol technical grade,usp/ep/jp grade.
Related News: Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company. 4-aza-3,4,7,7-tetramethyl-2,6-octadione manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2,4-Imidazolidinedione, 3-(2-phenylethyl)-5-(phenylmethylene)-, (5Z)- suppliers Denise Bowser, commercial director at Onyx, commented, “Over the years, we have worked towards building a strong reputation in helping drug developers with complex chemistry. 4-Oxazolecarboxylic acid, 5-(2-thienylmethyl)-, methyl ester vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2,4-Imidazolidinedione, 3-(2-phenylethyl)-5-(phenylmethylene)-, (5Z)- suppliers Denise Bowser, commercial director at Onyx, commented, “Over the years, we have worked towards building a strong reputation in helping drug developers with complex chemistry. 4-Oxazolecarboxylic acid, 5-(2-thienylmethyl)-, methyl ester vendor & factory.
